Pakistan vs Sudan: Average cost of drugs for extensively drug-resistant tuberculosis
Pakistan
1,923 constant 2022 US$
in 2024
Sudan
1,962 constant 2022 US$
in 2023
Pakistan rank
27th
Sudan rank
26th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Pakistan
- Sudan
How they compare
Sudan currently reports 1,962 constant 2022 US$ against 1,923 constant 2022 US$ in Pakistan, a difference of 39 constant 2022 US$.
The two have swapped places 1 time across 6 shared years of data; in 2018 it was Pakistan ahead.
Pakistan ranks 27th and Sudan ranks 26th of 56 countries.
Pakistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Pakistan | Sudan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 7,453 constant 2022 US$ | 5,080 constant 2022 US$ | 2,373 constant 2022 US$ | Pakistan |
| 2020s | 3,049 constant 2022 US$ | 1,672 constant 2022 US$ | 1,378 constant 2022 US$ | Pakistan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Pakistan or Sudan?
- Sudan, at 1,962 constant 2022 US$ against 1,923 constant 2022 US$ in Pakistan as of 2023.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Pakistan and Sudan?
- 39 constant 2022 US$, with Sudan ahead.
- How many years of comparable data are there for Pakistan and Sudan?
- 6 years are reported by both, from 2018 to 2023.
- How do Pakistan and Sudan rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Pakistan ranks 27th and Sudan ranks 26th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.